Entering text into the input field will update the search result below

Samsung Bioepis and Takeda team up to develop novel biologics

Aug. 21, 2017 7:01 AM ETBiogen Inc. (BIIB) StockBy: Douglas W. House, SA News Editor
  • Samsung Bioepis, the joint venture between Biogen (NASDAQ:BIIB) and Samsung BioLogics, and Takeda Pharmaceutical Company (OTCPK:TKPHF) ink a strategic collaboration agreement to jointly fund and co-develop novel biologic therapies to treat diseases with high unmet need.
  • The companies will begin working immediately on TAK-671 for the treatment of severe acute pancreatitis.
  • The partnership will leverage Takeda's drug development know-how with Samsung Bioepis' biologics development platform. Financial terms are not disclosed.

Recommended For You

More Trending News

About BIIB Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BIIB--
Biogen Inc.